Contents

Search

capecitabine (Xeloda)

Indications: 1) metastatic colon carcinoma (FDA approved)* 2) stage IV breast cancer (2nd-4th line agent) [2]* 3) inoperable advanced gastric cancer - in combination with a platinum-based regimen 4) ovarian cancer [3] 5) pancreatic adenocarcinoma 6) islet cell tumor [3] * Generic FDA-approved September 2013 [2] Dosage: Oral agent. Adverse effects: 1) diarrhea, nausea/vomiting - causes less diarrhea, nausea & mouth ulcers than 5-FU 2) pain, redness, swelling, or sores in the mouth 3) hand-&-foot syndrome - more likely than 5-FU to cause pain & swelling of the hands & feet - loss of fingerprints has been reported [4] 4) cutaneous lupus erythematosus [5] 4) fever or infection Drug interactios: - capecitabine may increase effect of warfarin [2] Mechanism of action: 1) metabolized to 5-fluorouracil (5-FU) 2) similar therapeutic effect as 5-FU

Related

5-fluorouracil [5-FU] (Fluoroplex, Efudex, Adrucel, Carac)

General

antineoplastic agent (chemotherapeutic agent) fluoropyrimidine

Properties

Database Correlations

PUBCHEM correlations

References

  1. Prescriber's Letter 8(7):40 2001
  2. FDA News Release: Sept. 16, 2013 FDA approves first generic capecitabine to treat colorectal and breast cancers
  3. Deprecated Reference
  4. Chavarri-Guerra Y, Soto-Perez-de-Celis E Images in clinical medicine. Loss of fingerprints. N Engl J Med. 2015 Apr 16;372(16):e22 PMID: 25875278 http://www.nejm.org/doi/full/10.1056/NEJMicm1409635
  5. Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015

Component-of

capecitabine/oxaliplatin (Xelox, Cape-Ox CAPOX)